InflaRx director reports initial shareholdings

InflaRx N.V. director Anthony S. Gibney filed an initial ownership report showing his equity stake.

Accepted by SEC EDGAR 03/18/2026 - 08:16 AM EDT

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

InflaRx N.V. director Anthony S. Gibney filed an initial ownership report showing his equity stake. He holds 10,000 Ordinary Shares directly, plus several stock options over Ordinary Shares with exercise prices between $1.17 and $2.41 per share that expire from 2028 through 2036. Many of these options, granted between 2018 and 2025, are fully vested and exercisable, while a 30,000-share option granted on January 6, 2026 will vest in four equal quarterly installments, subject to continued service.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Gibney Anthony S

Role Director

Type	Security	Shares	Price	Value
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Ordinary Shares	--	--	--

Holdings: Stock Option (Right to Buy) — 178,085 contracts (Direct); Ordinary Shares — 10,000 shares (Direct)

Footnotes (7)

F1. This option was granted on February 7, 2018 and is fully vested and exercisable as of the date hereof.
F2. This option was granted on July 2, 2021 and is fully vested and exercisable as of the date hereof.
F3. This option was granted on January 12, 2022 and is fully vested and exercisable as of the date hereof.
F4. This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof.
F5. This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof.
F6. This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof.
F7. This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 7,500 shares on each quarterly anniversary of such grant date, subject to continued service through such dates.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does InflaRx (IFRX) director Anthony S. Gibney report on this Form 3?

He reports initial ownership of 10,000 Ordinary Shares and multiple stock options. The options cover Ordinary Shares with exercise prices between $1.17 and $2.41, expiring from 2028 through 2036, reflecting his equity-based alignment with InflaRx.

How many InflaRx (IFRX) Ordinary Shares does Anthony S. Gibney hold directly?

He holds 10,000 Ordinary Shares directly. In addition to this share position, he has several stock option awards over Ordinary Shares at various exercise prices and expirations, providing additional potential ownership if he chooses to exercise those options.

What are the key terms of Anthony S. Gibney’s InflaRx (IFRX) stock options?

His options are rights to buy Ordinary Shares at fixed prices between $1.17 and $2.41. These options have expiration dates ranging from 2028 to 2036, giving him long-dated potential to acquire additional InflaRx equity at those strike prices.

Which of Anthony S. Gibney’s InflaRx (IFRX) options are already vested?

Options granted on February 7, 2018, July 2, 2021, January 12, 2022, January 24, 2023, January 5, 2024, and January 3, 2025 are fully vested and exercisable. This means he can already use these options to purchase Ordinary Shares at their stated exercise prices.

How does the January 6, 2026 InflaRx (IFRX) option grant vest for Anthony S. Gibney?

The option granted on January 6, 2026 for 30,000 underlying Ordinary Shares vests in four equal installments of 7,500 shares. Each installment vests on a quarterly anniversary of the grant date, contingent on his continued service through those vesting dates.

Does this InflaRx (IFRX) Form 3 show any insider buying or selling by Anthony S. Gibney?

It does not show buying or selling transactions; it records his existing holdings. The filing lists his direct ownership of 10,000 Ordinary Shares and his outstanding stock options, many of which are already vested and exercisable, as an initial beneficial ownership statement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Gibney Anthony S

(Last)

(First)

(Middle)

C/O INFLARX N.V.

WINZERLAER STREET 2

(Street)

JENA

07745

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
InflaRx N.V. [ IFRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	10,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	02/07/2028	Ordinary Shares	11,667	$1.86	D
Stock Option (Right to Buy)	⁽²⁾	07/01/2031	Ordinary Shares	16,418	$1.86	D
Stock Option (Right to Buy)	⁽³⁾	01/11/2032	Ordinary Shares	30,000	$1.86	D
Stock Option (Right to Buy)	⁽⁴⁾	01/24/2033	Ordinary Shares	30,000	$2.37	D
Stock Option (Right to Buy)	⁽⁵⁾	01/05/2034	Ordinary Shares	30,000	$1.79	D
Stock Option (Right to Buy)	⁽⁶⁾	01/03/2035	Ordinary Shares	30,000	$2.41	D
Stock Option (Right to Buy)	⁽⁷⁾	01/06/2036	Ordinary Shares	30,000	$1.17	D

Explanation of Responses:

1. This option was granted on February 7, 2018 and is fully vested and exercisable as of the date hereof.

2. This option was granted on July 2, 2021 and is fully vested and exercisable as of the date hereof.

3. This option was granted on January 12, 2022 and is fully vested and exercisable as of the date hereof.

4. This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof.

5. This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof.

6. This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof.

7. This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 7,500 shares on each quarterly anniversary of such grant date, subject to continued service through such dates.

Remarks:

Exhibit List - Exhibit 24.1 Power of Attorney

	/s/ Christian Schmid, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR